Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 11Thoracic 6Dermatologic 3Tumor-Agnostic 2Sarcoma 2Genitourinary 2Other 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Recurrence 1Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Spermine Synthase × Genitourinary × Clear all
NCT03075072 2024-10-23

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Dana-Farber Cancer Institute

Phase NA Active not recruiting
196 enrolled
BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Recurrence

NCT05324098 2024-06-10

Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy

University of California, San Francisco

Phase NA Completed
47 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡